News Summary: Abbott Labs hepatitis C drug study

Published



THE JUMP: Shares of Abbott Laboratories Inc. rose Monday after the company said an experimental five-drug regimen cured 99 percent of patients in a 12-week mid-stage clinical trial.

THE DATA: The North Chicago, Ill., company said the regimen worked on patients with the most common and hardest-to-treat type of the disease. The cocktail includes three experimental Abbott drugs as well as ribavirin, a standard component of hepatitis C treatment, and the antiviral drug Ritonavir.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.